News | Contrast Media | February 28, 2018

Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018

European conference marks global commercial launch of Contrast&Care to gather and share information on contrast products and procedures

Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018

February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other contrast media offerings for computed tomography (CT), the cath lab and magnetic resonance imaging (MRI), at the the 2018 European Congress of Radiology (ECR), Feb. 28-March 4 in Vienna, Austria.

Contrast&Care is a class I /CE medical device designed to be used by healthcare professionals only. It is a contrast media injection management solution that enables imaging centers to collect, archive, examine and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate (eGFR) and other risk factors before an exam. The solution enables all the information on injections during medical imaging examinations (contrast media, protocols, patient data, etc.) to be combined, and interfaces with the information systems used in radiology such as the radiology information system (RIS) and picture archiving and communication system (PACS) .

With this new solution, available in seven languages, Guerbet said it now features product offerings across the entire value chain. Contrast&Care complements Guerbet's digital services offering in synergy with Dose&Care, the operational solution for tracking patient exposure to ionizing rays. Contrast&Care and Dose&Care will be demonstrated at Guerbet's booth throughout the event.

For more information: www.guerbet.com

 

Related Content

Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
Characteristics nephrologists associate with renal high-risk patients. (n=13)

Characteristics nephrologists associate with renal high-risk patients. (n=13)

Feature | Contrast Media | September 05, 2019
The global rise in chronic disease has significantly increased demand for diagnostic imaging procedures, and in turn,
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...
Displacement comparison at the end-systolic frame and final frame

Displacement comparison at the end-systolic frame and final frame. The three patients (V6, V10, V16) with different left-ventricle walls are shown. Point-to-surface distance is a measure to estimate the distance of a point from the reference surface. Image courtesy of WMG, University of Warwick

News | Cardiac Imaging | August 28, 2019
A new 3-D magnetic resonance imaging (MRI) computing technique developed by scientists in WMG at the University of...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
Bracco Receives FDA Approval for Varibar Thin Liquid for Oral Suspension
Technology | Contrast Media | August 05, 2019
Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Videos | Digital Radiography (DR) | May 20, 2019
This is a quick walk-around video showing the ...